Reducing potential errors associated with insulin administration: An integrative review-Reference-Cited by-同舟云学术

Reducing potential errors associated with insulin administration: An integrative review

Published:2022-02-18 Issue:6 Volume:28 Page:1037-1049
ISSN:1356-1294
Container-title:Journal of Evaluation in Clinical Practice
language:en
Short-container-title:Evaluation Clinical Practice

Author:

Alqahtani Naji¹^ORCID

Affiliation:

1. Nursing Administration and Education Department, College of Nursing, King Saud University Riyadh Saudi Arabia

Funder

King Saud University

Publisher

Wiley

Subject

Public Health, Environmental and Occupational Health,Health Policy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jep.13668

Reference42 articles.

1. The Joint Commission. Sentinel Event Alert 11: High‐Alert Medications and Patient Safety. 2021.https://www.ismp.org/sites/default/files/attachments/2018-08/highAlert2018-Acute-Final.pdf

2. Impact of a clinical decision support system for high-alert medications on the prevention of prescription errors

3. Centers for Disease Control and Prevention. Estimates of Diabetes and its Burden in the United States. National Diabetes Statistics Report. 2020:32.

4. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients

5. National Estimates of Insulin-Related Hypoglycemia and Errors Leading to Emergency Department Visits and Hospitalizations

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Educational Interventions for Individuals with Insulin-Treated Type 2 Diabetes Mellitus: A Systematic Review;Patient Preference and Adherence;2024-09

2. Errors in diabetic insulin therapy and the vitality of proper precautions in Bangladesh: Real-life insights from the developing world;Journal of Family Medicine and Primary Care;2024-01

3. Transdermal Delivery of Insulin Using Combination of Iontophoresis and Deep Eutectic Solvents as Chemical Penetration Enhancers: In Vitro and in Vivo Evaluations;Journal of Pharmaceutical Sciences;2023-08

4. In type 1 diabetes, weekly basal insulin Fc was noninferior to daily insulin degludec for HbA_1c at 26 wk;Annals of Internal Medicine;2023-07

5. In type 2 diabetes, weekly basal insulin Fc was noninferior to daily insulin degludec for HbA_1c at 26 wk;Annals of Internal Medicine;2023-07